Details of the Drug Combinations

General Information of This Drug (ID: DMNQXV8)

Drug Name

LGX818 DMNQXV8

Synonyms

Encorafenib; 1269440-17-6; LGX-818; Encorafenib (LGX818); UNII-8L7891MRB6; LGX 818; 8L7891MRB6; Encorafenib [USAN:INN]; LGX-818(Encorafenib)

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Approved	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

4 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Arry-162 + LGX818	DC93UVB	Arry-162	Solid Tumors Harboring a BRAF V600 Mutation	[2]
LEE011 + LGX818	DCDNY6S	LEE011	Locally Advanced Metastatic BRAF Mutant Melanoma	[3]
LGK974 + LGX818	DCK529K	LGK974	Metastatic Colorectal Cancer	[4]
Arry-162 + LGX818	DCKBZVO	Arry-162	Melanoma	[5]
------------------------------------------------------------------------------------

References

1	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2	ClinicalTrials.gov (NCT01543698) A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
3	ClinicalTrials.gov (NCT01777776) Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
4	ClinicalTrials.gov (NCT02278133) Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations
5	ClinicalTrials.gov (NCT01909453) Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma